

Prior Authorization Criteria
Selective Transthyretin (TTR) Stabilizers

All requests for Selective Transthyretin (TTR) stabilizers require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Selective Transthyretin (TTR) stabilizers include: Vyndaqel (tafamidis meglumine), Vyndamax (tafamidis), Attruby (acoramidis) and Amvuttra (vutrisiran).

Coverage may be provided with a diagnosis of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the following criteria is met:

- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines
- The diagnosis is confirmed by presence of amyloid deposits on biopsy analysis from cardiac or non-cardiac sites (e.g., fat aspirate, gastrointestinal sites, salivary glands, bone marrow) or by technetium-labeled bone scintigraphy tracing
- Cardiac involvement was confirmed by echocardiography or cardiac magnetic resonance imaging (MRI) (e.g., end-diastolic interventricular septal wall thickness equal to or exceeding 12 mm)
- For members with hereditary ATTR-CM, presence of a mutation of the TTR gene was confirmed
- For members with wild type ATTR-CM, presence of transthyretin precursor proteins was confirmed by immunohistochemical analysis, scintigraphy, or mass spectrometry
- The member exhibits clinical symptoms of cardiomyopathy and heart failure (e.g., dyspnea, fatigue, orthostatic hypotension, syncope, peripheral edema)
- Member has a New York Heart Association Class I, II or III heart failure
- The member is not being treated with more than 1 selective transthyretin (TTR) stabilizer at a time.
- Must be prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis
- Member does not have a history of liver or heart transplantation
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 12 months
- **Reauthorization criteria**
 - Documentation confirming the member demonstrates a beneficial response to treatment (e.g., improvement on the 6-minute walk test, the Kansas City Cardiomyopathy Questionnaire—Overall Summary (KCCQ-OS) score, cardiovascular-related hospitalizations, NYHA classification of heart failure, left ventricular stroke volume, NT-proBNP level)
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or



Updated: 05/2025
PARP Approved: 06/2025

peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed.
These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



Updated: 05/2025
PARP Approved: 06/2025

SELECTIVE TRANSTHYRETIN (TTR) STABILIZERS PRIOR AUTHORIZATION FORM- PAGE 1 of 2

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Wholecare Pharmacy Services. **FAX:** (888) 245-2049

If needed, you may call to speak to a Pharmacy Services Representative. **PHONE:** (800) 392-1147 Mon – Fri 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	Provider NPI:
Provider Specialty:	Office Contact:
State license #:	Office NPI:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:

Is the member currently receiving requested medication? Yes No Date Medication Initiated:

Billing Information

This medication will be billed: at a pharmacy **OR** medically, JCODE: _____

Place of Service: Hospital Provider's office Member's home Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis: Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)

Other: _____ ICD-10 Code: _____

Has the diagnosis been confirmed by presence of amyloid deposits on biopsy analysis from cardiac or non-cardiac sites (e.g., fat aspirate, gastrointestinal sites, salivary glands, bone marrow) or by technetium-labeled bone scintigraphy tracing?

Yes No

Has cardiac involvement been confirmed by echocardiography or cardiac magnetic resonance imaging? Yes No

For members with hereditary ATTR-CM, has the presence of a TTR gene mutation been confirmed? Yes No

For members with wild type ATTR-CM, has the presence of transthyretin precursor proteins been confirmed by immunohistochemical analysis, scintigraphy, or mass spectrometry? Yes No

Does the member exhibit clinical symptoms of cardiomyopathy and heart failure (e.g., dyspnea, fatigue, orthostatic hypotension, syncope, peripheral edema)? Yes No

Does the member have a New York Heart Association Class I, II or III heart failure? Yes No

The member is not being treated with more than 1 selective transthyretin stabilizer? Yes No

Does the member have a history of liver or heart transplantation? (for requests for Vyndaqel and Vyndamax) Yes No

Is the medication being prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis? Yes No

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)



Updated: 05/2025
PARP Approved:06/2025

**SELECTIVE TRANSTHYRETIN (TTR) STABILIZERS
PRIOR AUTHORIZATION FORM (CONTINUED)– PAGE 2 of 2**

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Wholecare Pharmacy Services. **FAX:** (888) 245-2049

If needed, you may call to speak to a Pharmacy Services Representative. **PHONE:** (800) 392-1147 Mon – Fri 8:30am to 5:00pm

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REAUTHORIZATION

Is there documentation confirming the member has demonstrated a beneficial response to treatment (e.g., improvement on the 6-minute walk test, Kansas City Cardiomyopathy Questionnaire–Overall Summary (KCCQ-OS) score, cardiovascular-related hospitalizations, NYHA classification of heart failure, left ventricular stroke volume, NT-proBNP level)? Yes No

Prescribing Provider Signature

Date